Ciba-geigy Corporation

Bayer Aktiengesellschaft

Ucp Gen-pharma Ag

Plantorgan Werk Heinrich G. E. Christensen Kg

Novartis Ag

Novartis Corporation

Plantorganwerk Kg

Plantorgan-werk Heinrich G. F. Christensen, Kg

Hans Fritz

Johannes Dodt

Ursula Seemuller

Ernst Fink

Christian Sommerhoff

Jutta Heim

Hans Rink

Peter Sieber

Ronald Frank

Werner Rittel

Manfred Liersch

Sefik Alkan

Wolfgang Bruns

Helmut Blocker

Francois Meyer

John Collins

Rathindra Das

Walter M&auml;rki

Friedhelm Maywald

Ursula Seem&uuml;ller

Wolfgang Gebhard

The invention relates to DNA sequences which code an eglin, expression plasmids containing such DNA sequences, hosts transformed with such expression plasmids, novel eglin compounds produced from such transformed hosts, monoclonal antibodies against eglins, hybridoma cells which produce such antibodies, and test kits for immunoassays containing such antibodies, and furthermore the processes for their preparation and a process for the preparation of eglins with the aid of the transformed hosts. The eglins which can be prepared according to the invention have useful pharmacological properties.

Process for preparing recombinant eglin, protease inhibitor

Tryptase inhibitor

The present invention relates to novel inhibitors belonging to the family of antistasin-type serine proteinase inhibitors, to their isolation from the medical leech Hirudo medicinalis, to DNA sequences encoding the novel inhibitors, to variants obtained by recombinant DNA technology or peptide synthesis, pharmaceutical compositions containing the inhibitors, and to their use in diagnosis and therapy.

Antistasin type serine protease inhibitors

A proteinase inhibitor which has the sequence of amino acids 21 to 147 of human bikunin, in which at least one amino acid residue has been replaced by another naturally occurring amino acid. Such proteinase inhibitor is useful in pharmaceutical compositions.

Human Bikunin variants as proteinase inhibitors, and medicaments

The present invention relates to a peptide having essentially the amino acid sequence of pancreatic secretory trypsin inhibitor (PSTI). The present invention also relates to variants of such peptide wherein one or more of the amino acids in the original sequence are replaced by other amino acids. These peptides show an advantageously modified specificity in their inhibotory action. A method of preparation of the peptides and their pharmaceutical use is also described.

Pancreatic secretory tryspin inhibitor and variants thereof produced by

The present invention relates to desulfatohirudins, to the preparation thereof, to pharmaceutical compositions containing these compounds, and to the use thereof. The desulfatohirudins of this invention correspond to hirudin in biological activity and are therefore particularly useful for inhibiting blood clotting.

Method of inhibiting blood clotting with desulfatohirudins

Hirudin-PA and its derivatives, process for manufacturing these and the

Desulfatohirudins, the preparation thereof and pharmaceutical

Process for the preparation of desulfatohirudins

The invention relates to novel, modified eglins B and C, to the preparation thereof, and to pharmaceutical compositions which contain these compounds. Compared with eglin B and C, the modification consists in a terminal shortening. The compounds of the invention can be prepared e.g. by limited enzymatic proteolysis of elgins or by peptide synthesis.

Modified protease inhibitors, process for their preparation, and

Growing community of inventors

Hohenbrunn, Germany

Hans Fritz